Amicus Therapeutics, Inc. (FOLD) CEO John F. Crowley Sells 12,206 Shares of Stock
Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley sold 12,206 shares of the business’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $13.52, for a total value of $165,025.12. Following the completion of the transaction, the chief executive officer now owns 340,207 shares of the company’s stock, valued at approximately $4,599,598.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Amicus Therapeutics, Inc. (FOLD) traded down $0.05 during trading on Friday, reaching $12.85. The company had a trading volume of 3,449,116 shares, compared to its average volume of 1,637,163. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. Amicus Therapeutics, Inc. has a 12 month low of $4.41 and a 12 month high of $16.60.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). The firm had revenue of $10.90 million for the quarter, compared to analysts’ expectations of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The firm’s revenue was up 419.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.33) EPS. research analysts anticipate that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current year.
FOLD has been the subject of a number of research reports. Robert W. Baird reiterated an “outperform” rating and set a $16.00 price objective on shares of Amicus Therapeutics in a research report on Monday, September 25th. Zacks Investment Research cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 12th. Chardan Capital reiterated a “buy” rating and set a $16.50 price objective (down previously from $17.50) on shares of Amicus Therapeutics in a research report on Wednesday, September 13th. Bank of America upped their price objective on Amicus Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, October 4th. Finally, Goldman Sachs Group reiterated a “neutral” rating and set a $17.00 price objective on shares of Amicus Therapeutics in a research report on Friday, October 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $17.81.
COPYRIGHT VIOLATION WARNING: “Amicus Therapeutics, Inc. (FOLD) CEO John F. Crowley Sells 12,206 Shares of Stock” was published by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/amicus-therapeutics-inc-fold-ceo-john-f-crowley-sells-12206-shares-of-stock/1768332.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.